Avantor $AVTR claimed strength in biotech and life sciences but behind the beakers, they allegedly masked shrinking margins, lost key clients, and overstated growth. In this episode of Sue Wall Street, we break down the class action accusing Avantor of misleading investors, inflating valuations, and triggering a 25% stock slide. If you're into biotech markets, investor rights, or corporate accountability, don’t miss this one.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.